MagnetisMM-6
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)
Arms / Cohorts
Comparator:Part 2: Comparator Group: Daratumumab + Bortezomib + Lenalidomide + Dexamethasone
Not yet accepting
Experimental:Part 2: Experimental Group: Elranatamab + Daratumumab + Lenalidomide
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.